Neoantigen DNA vaccine - MedImmune/Washington University School of Medicine

Drug Profile

Neoantigen DNA vaccine - MedImmune/Washington University School of Medicine

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune; Washington University School of Medicine
  • Developer Washington University School of Medicine
  • Class Antigens; Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 10 Jul 2017 MedImmune and Washington University School of Medicine agree to co-develop neoantigen DNA vaccines in combination with checkpoint inhibitors and other immunotherapy agents for Cancer
  • 22 Jun 2017 Washington University School of Medicine plans a phase I trial for Breast cancer (Second-line therapy and greater, Monotherapy, Combination therapy) in USA on 30 September 2017 (NCT03199040)
  • 22 Jun 2017 Preclinical trials in Breast cancer in USA (IM) before June 2017 (NCT03199040)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top